Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financi... (11118) $(71804) Adjustments to reco...)

Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results

Date:11/6/2008

11,118) $(71,804)

Adjustments to reconcile net loss to

net cash used in operating activities:

Stock-based compensation 6,955 11,712

Depreciation and amortization 18,610 22,964

Loss on equity investment 705 -

Foreign currency transaction loss 428 -

Loss on sale or disposal of assets 282 1,776

Amortization of gain related to sale of building (656) (656)

Changes in assets and liabilities:

Decrease (increase) in trade accounts receivable 13,122 10,343

Decrease (increase) in inventories 2,326 (2,519)

Decrease (increase) in prepaids and other assets 2,659 6,846

Increase (decrease) in accounts payable (1,476) (2,784)

Increase (decrease) in accrued compensation (229) (2,170)

Increase (decrease) in accrued

expenses to contract manufacturers (40,444) -

Increase (decrease) in accrued expenses 3,269 6,622

Increase (decrease) in interest payable (2,553) (2,684)

Increase (decrease) in deferred revenue (11,972) 61,777

Increase (decrease) in other liabilities 5,027 152

Net cash used in operating activities (115,065) 39,575

Cash flows from investing activities:

Purchases of investments (411,417) (342,807)

Maturities of investments 506,348 468,245

Sales of investments 28,590 -

Purchases of property and equipment (15,064) (21,030)

Investment in Pearl Therapeutics Inc. (4,236) -

Net
'/>"/>

Post Your Comments:

Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financi...(11118) $(71804) Adjustments to reco...),Health